Division of Gastroenterology, Hepatology and Nutrition Research. Research. Matthew Cave, M.D. Cave Research. Cave Research
|
|
|
- Arthur Dixon
- 6 years ago
- Views:
Transcription
1 Division of Gastroenterology, Hepatology and Nutrition Matthew Cave, M.D. Cave Industry Sponsored Clinical Trials Merck (hepatitis C protease inhibitor) Intercept (PBC FXR agonist) Sucampo (Wo, cytokines in motility disorder) Cave Liver Opportunities Occupational/Environmental Liver Disease Alcoholic Liver Disease Industry Sponsored Clinical Trials Cave Alcoholic Liver Disease Zinc supplementtion for alcoholic cirrhosis. K23AA A. $990,436. Epigenetic mechanisms of ethanol-induced immune suppression (Shirish( Barve). National Institutes of Health Extramural Loan Repayment Program for Clinical (NIAAA). Cave Industry Sponsored Clinical Trials Merck (hepatitis C protease inhibitor) Intercept (PBC FXR agonist) Sucampo (Wo, cytokines in motility disorder)
2 Cave Occupational/Environmental Liver Disease Hepatic hemangiosarcoma biomarkers: Rubbertown workers. UofL/Commonwealth of Kentucky CTSPGP advanced Award. $98,007. PCB s s and organochlorine pesticides in obesity, diabetes, and NAFLD: Mouse and cell culture. NCRR 5P20RR $405,404. Identification (rubbertown workers) and mechanisms (mitochondrial toxicity / necrosis) of toxicant-associated associated steatohepatitis (TASH) Environmental liver disease (NHANES). Craig McClain,, M.D. McClain Abnormal methionine metabolism in liver disease McClain Human NIH Trials (SAH) Methyl acceptor (SAM ) 1. SAMe therapy ALD 2. SAMe therapy NASH 3. Biochemical profile NASH 4. Cytokine response NASH 5. Cytokine/Trental Rx in ALD McClain Animal Studies 1. Obesity NAFLD 2. Drug therapy NAFLD/ASH Article/Chapters 1. Nutrition Liver Disease 2. Therapy for Alcoholic Hepatitis 3. HAART Hepatotoxicity Richard Redinger, M.D.
3 Redinger Publications in preparation Cholesterol catabolism advances in its understanding The conundrum of common but complex polygenesis obesity John Wo, M.D. Wo Investigator-Initiated Initiated Trials Gastroparesis Idiopathic gastroparesis registry to define severity, treatment response and prognosis using a predominant-symptoms classification Underlying causes of vomiting-predominant symptoms of unclear etiology Domperidone Wo Investigator-Initiated Initiated Trials High Resolution Esophageal Manometry Correlation with symptoms Barrett s s Esophagus Registry, Biorepository Evaluation of curcumin in patients with dysplastic Barrett s s esophagus Wo Industry-Sponsored Trials Diarrhea-predominant IBS with K opiod agoinist Prevention of diverticulitis recurrence with 5-ASA Shirish Barve,, PhD
4 Predictive Power of Gene Methylation: Early Detection of HCC Novel Endoscopic Overtube Tad Dryden, MD, MSPH, MSc Currently undergoing development of prototype Animal trial anticipated in months Will need assistance with recording, analysis, writing of abstract/manuscript Assistance with regulatory paperwork
5 Novel Endoscopic Bariatric Device Will begin work on prototype in months Funded for development of prototype Funded for acute animal trial Will need assistance with development, animal trial, analysis, abstract/manuscript production Anti-TNF Therapy to Reduce Colon Tumor Formation Animal study using AOM/DSS in WT animals Animals regularly treated with anti-tnf antibody during course of inflammation Undergo periodic endoscopy Analyze for macrophage phenotype, angiogenesis markers Will need assistance with any aspect Adipose-Derived Mesenchymal Stem Cells for Fistulizing CD Active IACUC Currently evaluating stem cell infiltration into matrix plug vs electrospun fibrinogen Anticipate animal trial within months Will need assistance with data collection, analysis, abstract/manuscript preparation Industry Sponsored Trials Vedolizumab for moderate to severe ulcerative colitis Vedolizumab for moderate to severe Crohn s s disease Investigator Initiated Trials Green tea polyphenol extract in mild to moderate ulcerative colitis Resources CREST program and- pdfs/uofl%20crest%20student%20handb ook%20-july% pdf Division of Infectious Disease Program ocman&itemid=87
6 Requirements BRAAN COI HIPAA on.html CITII aining/human-subjects subjects-training-citi.html Requirements Animal Safety Chemical and Radiologic Safety Blood Born Pathogens
2017 NEEDS ASSESSMENT SURVEY
2017 NEEDS ASSESSMENT SURVEY Quick Overview: Educational Topic Findings The online 2017 Needs Assessment survey was programmed through SurveyMonkey and a personalized request to complete the questionnaire
FDA Introductory Remarks Stephanie O. Omokaro, MD
FDA Introductory Remarks Stephanie O. Omokaro, MD Division of Gastroenterology & Inborn Errors Products (DGIEP) Center for Drug Evaluation and Research Office of New Drugs Office of Drug Evaluation III
Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology
Lahey Clinic Internal Medicine Residency Program: Curriculum for Gastroenterology Faculty representative: David L. Burns, MD, CNSP Resident representative: Tom Castiglione, MD Revision date: March 6, 2006
2017 Canadian Association of Gastroenterology Educational Needs Assessment Report
2017 Canadian Association of Gastroenterology Educational Needs Assessment Report Kevin A. Waschke MD., CM., FRCPC, FASGE VP Education Affairs, Canadian Association of Gastroenterology Karen Sparkes BASc
Gastroenterology. Certification Examination Blueprint. Purpose of the exam
Gastroenterology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified gastroenterologist
Improving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease
Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease Scott Friedman, M.D. Fishberg Professor of Medicine Dean for Therapeutic Discovery Chief, Division of Liver Diseases Icahn School of
Research in IBD at University of Colorado Denver
Research in IBD at University of Colorado Denver Blair Fennimore, MD Assistant Professor of Medicine Division of Gastroenterology and Hepatology UCH Crohn s and Colitis Center Mucosal Inflammation Program
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
Conference Location 505 S. Hancock Street. Parking at the Conference. changes. and Syllabus. any last minute room. Seminar Agenda. made.
2019 Emerging Therapies for PBC, NASH, ESLD and HCC Seminar Series Louisville, Kentucky February 9, 2019 Conference Location Kosair Charities Clinical & Translational Research Building Classroom 101 and
METABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
AESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
Program Schedule Template Monday, February 23, 2015 Time Topic 7:00 a.m. Registration and Continental Breakfast 7:30 a.m. Welcome and Introductions
Program Schedule Template Monday, February 23, 2015 7:00 a.m. Registration and Continental Breakfast 7:30 a.m. Welcome and Introductions William Sanchez, M.D., Shabana F. Pasha, M.D. and Michael F. Picco,
GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint
GASTROENTEROLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Gastroenterology MOC exam blueprint Based on feedback from physicians that MOC assessments
Spring 2017 Health & Wellness Seminar Series. Seminar 1: April 25 th, 2017
Spring 2017 Health & Wellness Seminar Series Seminar 1: April 25 th, 2017 1 Breakthroughs in Screening & Treatment of Liver Disease: From Hepatitis C and Fatty Liver Disease to Liver Cancer Robert S. Brown,
The Norwegian PSC Research Center Biobank
The Norwegian PSC Research Center Biobank Trine Folseraas Norwegian PSC Research Center, Department of Transplantation Medicine, Division of Surgery, Inflammatory Medicine and Transplantation, Oslo University
Liver Transplant Pathology a general view
Liver Transplant Pathology a general view Dr S E Davies Addenbrooke s Hospital Cambridge University Hospitals NHS Trust ACP/BSG Meeting Leeds 2012 Liver transplantation When and where? Who and why? How?
Key uncertainties around the evidence or technology are that the test has only been validated in biochemical studies.
pat hways PredictSure-IBD for inflammatory bowel disease prognosis Medtech innovation briefing Published: 25 March 2019 nice.org.uk/guidance/mib178 Summary The technology described in this briefing is
GASTROINTESTINAL IMAGING STUDY GUIDE
GASTROINTESTINAL IMAGING STUDY GUIDE Pharynx Diverticula Foreign bodies Trauma o Motility Disorders Esophagus Diverticula Trauma Esophagitis Barrett esophagus Rings, webs, and strictures Varices Benign
Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
NEURO- GASTRO- ENTEROLOGY & MOTILITY OESO- PHAGUS LOGY. Room A Room B Room C Room E1 Room E2 Room M Room N1 Room N2 Room L8 Room 1.
ONCO ENTERO RADIO & SATURDAY SUNDAY MONDAY TUESDAY WEDNESDAY Saturday, October 15, 2016 Room A Room B Room C Room E1 09:00-10:30 Peptic ulcer : Still important for gastroenterologists 11:00-13:00 Video
Defining the gold standard in biomarker validation for NASH
Defining the gold standard in biomarker validation for NASH Arun J Sanyal M.D. Professor of Medicine, Physiology and Molecular Pathology Virginia Commonwealth University School of Medicine Conflicts of
Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
Bariatric Surgery and Liver Transplantation
Bariatric Surgery and Liver Transplantation Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery Head, Outcomes Research in Hepatology David Geffen School of Medicine at UCLA Disclosures
Fatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
CURRENT RESEARCH STUDIES (GI and Hepatology Clinical Research Office University of Wisconsin)
CURRENT RESEARCH STUDIES (GI and Hepatology Clinical Research Office University of Wisconsin) OPEN TO ENROLLMENT: Liver Studies Seroprevalence of Hepatitis E in Organ Transplant subjects PI: Michael Lucey
IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
Role of Nutritional Support in the Treatment of Alcoholic Liver Disease
Riunione Monotematica AISF Alcoholic Liver Disease: The New Challenge Roma, 4-6 Ottobre 2017 Role of Nutritional Support in the Treatment of Alcoholic Liver Disease Esmeralda Capristo Divisione di Patologie
AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
Management of alcoholic hepatitis: Implications for options beyond the STOPAH study
Management of alcoholic hepatitis: Implications for options beyond the STOPAH study Gyongyi Szabo, MD, PhD Professor University of Massachusetts Medical School Worcester, MA Cape Town, South Africa 2015
Thank You. Presented By. Title Sponsor. Venue Host
Thank You Presented By Title Sponsor Venue Host NIDDK Research: Opportunities for Partnering Vladimir Knezevic, M.D. Senior Advisor for Commercial Evaluation, Technology Advancement Office, National Institute
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
Fecal incontinence causes 196 epidemiology 8 treatment 196
Subject Index Achalasia course 93 differential diagnosis 93 esophageal dysphagia 92 95 etiology 92, 93 treatment 93 95 work-up 93 Aminosalicylates, pharmacokinetics and aging effects 36 Antibiotics diarrhea
Study Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH
Study Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology
Gastroesophageal Reflux Disease in Infants and Children
Gastroesophageal Reflux Disease in Infants and Children 4 Marzo 2017 Drssa Chiara Leoni Drssa Valentina Giorgio pediatriagastro@gmail.com valentinagiorgio1@gmail.com Definitions: GER GER is the passage
Lipid and Bile Acids as NAFLD- Related Biomarkers
Lipid and Bile Acids as NAFLD- Related Biomarkers Puneet Puri, MBBS, MD Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University, Richmond, VA 1st International Workshop
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
Forward-looking Statements
NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements
Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R.
UvA-DARE (Digital Academic Repository) Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults Hoekman, D.R. Link to publication Citation for published version
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
Non-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
GASTROENTEROLOGY ESSENTIALS
GASTROENTEROLOGY ESSENTIALS Practical Gastroenterology 8/25/2018 Jahnavi Koppala, MBBS Abdullah Abdussalam, MD A 48-year-old male was evaluated for noncardiac chest pain. Treatment with PPI twice daily
ACG'S IBD SCHOOL EASTERN REGIONAL
ACG'S IBD SCHOOL EASTERN REGIONAL & 2017 POSTGRADUATE COURSE MARRIOTT MARQUIS, APRIL 7 9, 2017 WASHINGTON, DC EASTERN REGIONAL POSTGRADUATE COURSE EARN UP TO EARN 10.75 10.75 UP TO CME CREDITS IBD School
Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways
Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways Department of Gastroenterology, Endocrinology & Metabolism Medical University Innsbruck Herbert Tilg Nothing to disclose Fig.
Gastroenterology Fellowship Program
Gastroenterology Fellowship Program Outpatient Clinical Rotations I. Overview A. Three Year Continuity Clinic Experience All gastroenterology fellows will be required to have a ½ day continuity clinic
Metabolic Syndrome and HCC. Jacob George
Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For
Inflammation in the clinic
Inflammation in the clinic Stephen T. Holgate MRC Clinical Professor of Immunopharmacology ILSI Europe Workshop, Seville, May 14-15 2012 The immune system acts in four general ways to ensure host defence
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that
The impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
Gastroenterology and Feeding Issues in Fanconi Anemia
Gastroenterology and Feeding Issues in Fanconi Anemia Sarah Jane Schwarzenberg, MD Pediatric Gastroenterology, Hepatology and Nutrition August 12, 2012 GI problems in FA 5% have gastrointestinal tract
Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
Cholesterol and Sphingolipids in Non-Alcoholic fatty liver disease.
Cholesterol and Sphingolipids in Non-Alcoholic fatty liver disease. José C. Fernández-Checa Liver Unit, Hospital Clinic CIBEK and IDIBAPS Instituto Investigaciones Biomédicas Barcelona Consejo Superior
NASH UPDATE ON DIAGNOSTICS AND THERAPY. Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine
NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute,
Hepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
OST575 Course Schedule US2017
OST575 Course Schedule US2017 Updated 6/14/17 SG EXAM 1 LIVE & ONLINE LECTURE CONTENT 5/15/17 1:00-1:50PM ONLINE 28:27 1. Anatomy: Esophagus/Stomach Pratt 5/17/17 9:00-9:50AM EL E105 2. Introduction to
F A M N O P R S ! D !
A B C D E F A M N O P Q G H I J R S T U V 595 W http://www.encognitive.com/images/digestive-system-2.jpg K L M A N B C O P D E F G D Q R H S I J K http://apbrwww5.apsu.edu/thompsonj/anatomy%20&%20physiology/2020/2020%20exam%20reviews/exam%203/colon%20diagram.jpgd
NAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
Featured Topic: Get Digestive Relief (and more) with Probiotics (4 slides)
Featured Topic: Get Digestive Relief (and more) with Probiotics (4 slides) 3 things you need to know about probiotics Probiotics are helpful bacteria Probiotics prevent disease, they don t cause it (bad
Liver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine
Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived
Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura
Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Sourasky Medical Center Tel Aviv, Israel IBD- clinical features
NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF
NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF Royal Armouries International, Leeds 17 June 2015 17 th Annual Conference of
Esophageal Disorders. Gastrointestinal Diseases. Peptic Ulcer Disease. Wireless capsule endoscopy. Diseases of the Small Intestine 7/24/2010
Esophageal Disorders Gastrointestinal Diseases Fernando Vega, MD HIHIM 409 Dysphagia Difficulty Swallowing and passing food from mouth via the esophagus Diagnostic aids: Endoscopy, Barium x ray, Cineradiology,
Regulatory update from Europe:
Regulatory update from Europe: Interim endpoints in phase 3 NASH trials Elmer Schabel MD The previously proposed/presented co-primary evaluation of two composite endpoints for the interim has been accepted:
Conflicts of Interest in the last 12 months
STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last
A Case of Inflammatory Bowel Disease
A Case of Inflammatory Bowel Disease Dr Barrie Rathbone www.le.ac.uk 26 year old Polish woman Admitted as emergency under surgeons RUQ and RIF pain Abdominal pain had occurred intermittently for a few
TAKEDA GASTROENTEROLOGY A GLOBAL LEADER IN GASTROENTEROLOGY
TAKEDA GASTROENTEROLOGY A GLOBAL LEADER IN GASTROENTEROLOGY ASIT PARIKH MD, PHD Head, Gastrointestinal Therapeutic Area WE ARE A LEADING GI COMPANY GASTROENTEROLOGY OUR VISION Restore Life to Living for
TAKEDA GASTROENTEROLOGY A GLOBAL LEADER IN GASTROENTEROLOGY. ASIT PARIKH MD, PHD Head, Gastrointestinal Therapeutic Area
TAKEDA GASTROENTEROLOGY A GLOBAL LEADER IN GASTROENTEROLOGY ASIT PARIKH MD, PHD Head, Gastrointestinal Therapeutic Area WE ARE A LEADING GI COMPANY GASTROENTEROLOGY OUR VISION Restore Life to Living for
WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF
WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi
NAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States
GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY
Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
Liver biopsy as the gold standard for diagnosis. Pierre BEDOSSA
Liver biopsy as the gold standard for diagnosis Pierre BEDOSSA 1 PATHOLOGY OF NAFLD CONFLICTS OF INTEREST Grants and funding from Genfit, Intercept, Allergan, Inventiva, OWL, Echosens CEO and funding of
NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
Enrolling Research Studies 15 November 2017
Enrolling Research Studies 15 November 2017 Crohn s Disease/ Ulcerative Colitis Humira (AbbVie) Crohn s Disease (Eli Lilly) Ulcerative Colitis (Genentech) Crohn s Disease (Genentech) Crohn s Disease /
Indications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
Testimony Submitted by: Eric Zuckerman, DO Bloomfield Hill, MI Board Chairman, Pediatric IBD Foundation
Testimony Submitted by: Carlo Di Lorenzo, MD Nationwide Children s Hospital, Columbus, OH President, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Benjamin Gold, MD, Children's
2012 POSTGRADUATE COURSE SYLLABUS
2012 POSTGRADUATE COURSE SYLLABUS Program Description, Faculty Listing and Disclosure Information...vii Course Evaluation and CME Information...xi SATURDAY MORNING, OCTOBER 20, 2012 Session 1A: Upper GI
Last Revised: September 15 Last Reviewed: September EOSINOPHILIC ESOPHAGITIS (EOE)/PPI-RESPONSIVE ESOPHAGEAL EOSINOPHILIA (PPI-REE)
7.0 GASTROENTEROLOGY Last Revised: September 5 Last Reviewed: September 5 7. EOSINOPHILIC ESOPHAGITIS (EOE)/PPI-RESPONSIVE ESOPHAGEAL EOSINOPHILIA (PPI-REE) Significant changes: ) Addition of PPI-REE as
Bleeding in the Digestive Tract
Bleeding in the Digestive Tract National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH U.S. Department of Health
Crohn s Disease: A New Approach to an Old Problem
Management of Postoperative Crohn s Disease: A New Approach to an Old Problem Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center
Epidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry
Epidemiology of IBD in Pediatric Patients in the US: Data from the ImproveCareNow Registry Michael D. Kappelman, MD Professor of Pediatrics and Epidemiology University of North Carolina, Chapel Hill Richard
PA SYLLABUS FACULTY OF MEDICINE NB II PROGRAM STUDY DEPARTMENT OF INTERNAL MEDICINE DISCIPLINE OF GASTROENTEROLOGY
Pag. 1 / 10 FACULTY OF MEDICINE NB II PROGRAM STUDY DEPARTMENT OF INTERNAL MEDICINE DISCIPLINE OF GASTROENTEROLOGY APPROVED At the meeting of Extract from minutes no of 2018 Head of Department PhD,associate
Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
IBD What s in it for you?
Addenbrooke s NHS Trust IBD What s in it for you? Dr Miles Parkes Consultant Gastroenterologist Cambridge What is IBD? - inflammatory bowel disease Ulcerative colitis + Crohn s disease = main forms Incidence
LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
FOR REVIEW. BMB Reports - Manuscript Submission. Manuscript Draft. Manuscript Number: BMB
BMB Reports - Manuscript Submission Manuscript Draft Manuscript Number: BMB-18-095 Title: Insulin Receptor Substrate 2:A Bridge between Hippo and AKT Pathways Article Type: Perspective (Invited Only) Keywords:
Chapter 32 Gastroenterology General Pathophysiology General Risk Factors for GI emergencies: Excessive Consumption Excessive Smoking Increased
1 2 3 4 5 6 7 Chapter 32 Gastroenterology General Pathophysiology General Risk Factors for GI emergencies: Excessive Consumption Excessive Smoking Increased Ingestion of Caustic Substances Poor Bowel Habits
Understanding Root Cause: Pathogenesis of Hepatic Fibrosis
10/1/12 Understanding Root Cause: Pathogenesis of Hepatic Fibrosis Hepatitis C Virus Mild inflammation Inflammation Fibrosis Cirrhosis 1 10/1/12 Non-alcoholic Fatty Liver Disease Steatosis Steatohepatitis
Complementary & Alternative Therapies in IBD
Complementary & Alternative Therapies in IBD Laurie Rosales, APRN-CNP OSU Wexner Medical Center Division of Gastroenterology, Hepatology and Nutrition Complementary & Alternative Probiotics Cannabis Fish
Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding: